Contributions
Abstract: EP1439
Type: ePoster
Abstract Category: Clinical aspects of MS - 11 Comorbidity
Introduction: Neuromyelitis optica (NMO) is a female-predominant autoimmune disorder of CNS with a disease-specific antibody against CNS water channel, aquaporin 4 (AQP4). Patients with NMO experience reduced mobility and are susceptible to falls; moreover, many patients are being treated with glucocorticoids which are known risk factors for osteoporosis. However, there is no study for osteoporosis in NMO. This study aims to investigate the frequency of the osteoporosis and the association between bone mineral density (BMD) and disease disability, glucocorticoid use, or disease duration in NMO.
Methods: Bone mineral density (BMD) was measured by dual x-ray absorptiometry in patients, who were diagnosed as NMO spectrum disorder (NMOSD) with anti-AQP4 antibody (anti-AQP4). We analyzed clinical features including the Expanded Disability Status Scale (EDSS) score, cumulating steroid dose, annual relapse rate (ARR), and body mass index(BMI).
Results: A total of 37 patients (mean age, 48.89±13.98 years; F:M =36:1) were included in this study. The disease duration at the time of BMD test was 8.86±6.57 years. BMD was correlated with the EDSS score (r2 = 0.172, p=0.10) and the BMI at the time of BMD test. (r2 = 0.078, p=0.016) However, BMD was not correlated with age, disease duration, and the total dosage of steroid. The incidence of osteopenia and/or osteoporosis was significantly higher, compared to normal population, according to the ages (10-19 years, 67% vs %; 20-29 years, 63% vs ; 30-39 year, 86% vs ; 40-49 years, 86% vs %; 50-59 years, 86% vs %; 60-69 years; 67% vs %).
Conclusion: Our study showed that NMO patients had higher frequency of low bone mass compared with normal population, even at an early age and BMD was correlated with disease severity and BMI. Since low BMD was present in NMO patients at their early age, NMO patients should be screened for early detection and treatment, particularly with high disease severity and low BMI.
Disclosure: nothing to disclose
Abstract: EP1439
Type: ePoster
Abstract Category: Clinical aspects of MS - 11 Comorbidity
Introduction: Neuromyelitis optica (NMO) is a female-predominant autoimmune disorder of CNS with a disease-specific antibody against CNS water channel, aquaporin 4 (AQP4). Patients with NMO experience reduced mobility and are susceptible to falls; moreover, many patients are being treated with glucocorticoids which are known risk factors for osteoporosis. However, there is no study for osteoporosis in NMO. This study aims to investigate the frequency of the osteoporosis and the association between bone mineral density (BMD) and disease disability, glucocorticoid use, or disease duration in NMO.
Methods: Bone mineral density (BMD) was measured by dual x-ray absorptiometry in patients, who were diagnosed as NMO spectrum disorder (NMOSD) with anti-AQP4 antibody (anti-AQP4). We analyzed clinical features including the Expanded Disability Status Scale (EDSS) score, cumulating steroid dose, annual relapse rate (ARR), and body mass index(BMI).
Results: A total of 37 patients (mean age, 48.89±13.98 years; F:M =36:1) were included in this study. The disease duration at the time of BMD test was 8.86±6.57 years. BMD was correlated with the EDSS score (r2 = 0.172, p=0.10) and the BMI at the time of BMD test. (r2 = 0.078, p=0.016) However, BMD was not correlated with age, disease duration, and the total dosage of steroid. The incidence of osteopenia and/or osteoporosis was significantly higher, compared to normal population, according to the ages (10-19 years, 67% vs %; 20-29 years, 63% vs ; 30-39 year, 86% vs ; 40-49 years, 86% vs %; 50-59 years, 86% vs %; 60-69 years; 67% vs %).
Conclusion: Our study showed that NMO patients had higher frequency of low bone mass compared with normal population, even at an early age and BMD was correlated with disease severity and BMI. Since low BMD was present in NMO patients at their early age, NMO patients should be screened for early detection and treatment, particularly with high disease severity and low BMI.
Disclosure: nothing to disclose